TNFRSF8 and Hodgkins lymphoma: For R/R CD30‐positive HL patients prior to ASCT, the phase 2 NCT01393717 study demonstrated that an ORR of 68%, besides, 49% of patients received ASCT without salvage chemotherapy.70